BioPlus Co Ltd
KOSDAQ:099430
BioPlus Co Ltd
Total Receivables
BioPlus Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Total Receivables
₩21.2B
|
CAGR 3-Years
36%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Total Receivables
₩146.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
|
SD Biosensor Inc
KRX:137310
|
Total Receivables
₩171.4B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Total Receivables
₩17.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
Total Receivables
₩11.6B
|
CAGR 3-Years
17%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
5%
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Total Receivables
₩18.6B
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Total Receivables?
Total Receivables
21.2B
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Total Receivables amounts to 21.2B KRW.
What is BioPlus Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
39%
Over the last year, the Total Receivables growth was -9%. The average annual Total Receivables growth rates for BioPlus Co Ltd have been 36% over the past three years , 39% over the past five years .
